跳至主要内容
临床试验/NCT06405295
NCT06405295Enrolling By Invitation不适用

A Multicentre Prospective Cohort Study: Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2024年5月6日最近更新:

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
600
试验地点
1
主要终点
iDFS%

研究概览

简要总结

Evaluation of the efficacy and safety of different adjuvant intensification regimens in early-stage BRCA1/2 mutant triple-negative breast cancer.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • ECOG score 0-1
  • BRCA1/2 mutation
  • No distant metastases assessed by imaging after surgical treatment
  • Breast cancer that is non-pCR after neoadjuvant therapy, or postoperative pathology suggestive of ≥pT2, or ≥pN1
  • Have completed postoperative adjuvant chemotherapy and/or radiotherapy
  • No major organ dysfunction

排除标准

  • Patients who are unable to take oral medication, or who refuse this medication regimen
  • Already enrolled in another study, or less than or equal to 4 weeks from discontinuation of another medication
  • Presence of severe dysfunction of vital organs
  • Patients with other malignancies (with the exception of cured non-melanoma skin cancers, carcinoma in situ of the cervix and other tumours that have been cured for at least 5 years)
  • Acute infectious disease or active chronic infectious disease
  • History of uncontrolled epilepsy, central nervous system disease or mental disorder

结局指标

主要结局

iDFS%

时间窗: 3 years

次要结局

  • DRFS%(3 years)
  • OS%(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

PENG YUAN

Professor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

研究点 (1)

Loading locations...

相似试验